A method of preparing a single-phase modified sodium hyaluronate gel, comprising preparing a sodium hyaluronate solution with a mass fraction between 5% to 15% in an alkaline condition at a pH value between 11 to 14, wherein the sodium hyaluronate has a molecular weight between 1.5 million to 4 million Daltons; adding a cross-linking agent to a solution of step (1), wherein the cross-linking agent and the sodium hyaluronate has a molar ratio between 9% to 15%; rapidly mixing for 20 to 40 minutes to form a gel; allowing to stand after subjecting to a water bath at constant temperature; dialyzing with a dialysis membrane to remove un-reacted cross-linking agent and hydroxide ion; homogenizing; and adding a mobile phase and mixing sufficiently to obtain a high viscosity stabilized single-phase modified sodium hyaluronate gel.

Nitric oxide-releasing materials, methods of making nitric oxide-releasing materials, and uses of nitric oxide-releasing materials are provided. The nitric oxide-releasing materials include a mesoporous silica core and an outer surface having a plurality of nitric oxide donors. In an exemplary aspects, the nitric oxide-releasing material includes a mesoporous diatomaceous earth core, and an outer surface having a plurality of S-nitroso-N-acetyl-penicillamine groups covalently attached thereto. Uses of the nitric oxide-releasing materials can include coatings for medical devices such as catheters, grafts, and stents; wound gauzes; acne medications; and antiseptic mouthwashes; among others.

A process is described for the purification of HA, and pharmaceutical, cosmetic and nutritional compositions containing HA thus purified.

The present invention provides a method of preparing biomembrane, closed structure with biomembrane characteristics or cellular compartment, comprising the following steps: 1), acquire biological cells from natural tissues or natural biological species; 2), culture the cells obtained in step 1) massively in an appropriate environment; 3), acquire the lysates of cells in step 2), and extracting the biomembrane, closed structure with biomembrane characteristics and cellular compartment through differential centrifugation, density gradient centrifugation or dual-phase extraction individually or a combination of two methods or a combination of three methods thereof. The membrane is a natural biomembrane, closed structure with biomembrane characteristics and cellular compartment, which can be used for package of active ingredients in various fields.

The present disclosure relates to a hydroxyapatite obtained from porous wood, having high compressive strength and dimensions suitable for clinical applications. The porous wood has a porosity of between about 60% and about 95%, said porosity being measured after subjecting the wood to a step of pyrolysis, and is selected from among rattan, pine, abachi, balsa, sipo, oak, rosewood, kempas and walnut wood. The hydroxyapatite may be substituted with one or more ions such as magnesium, strontium, silicon, titanium, carbonate, potassium, sodium, silver, gallium, copper, iron, zinc, manganese, europium, gadolinium. Also disclosed is a bone substitute comprising hydroxyapatite obtained from porous wood. The bone substitute is utilized for the substitution and regeneration of a bone or a bone portion, preferably for bones subjected to mechanical loads, such as long bones of the leg and arm, preferably the tibia, fibula, femur, humerus and radius. The invention relates also to a process for manufacturing a biomorphic hydroxyapatite scaffold from wood.

Implant devices are coated with biologically active compounds, in particular with plant extracts from vinification residues. The implant devices are bone implants, and in particular dental implants. A method for functionalizing a surface of an implant device is includes the steps of a) optionally, treating the surface of the implant device with air, oxygen, argon, nitrogen plasma, and plasma capable of removing the surface layer of hydrocarbon contamination, b) treating the surface of the implant with an amine substrate, c) treating the surface of the implant resulting from step b), alternatively with a marcs extract, and drying the functionalized surface, or by co-adsorbing a marcs extract and hyaluronic acid, and drying the functionalized surface, or by adsorbing hyaluronic acid and post-adsorbing a marcs extract, and drying of the functionalized surface.

This invention provides optimized solid substrates for promoting cell or tissue growth or restored function and uses of same, which in some aspects address a need in populations at greater risk for osteochondral, bone or cartilage disease, or in some embodiments, in subjects for whom no effective therapeutic or surgical intervention exists, or in some embodiments, in subjects for whom recovery from and/or quality of life after therapeutic intervention is not significantly improved, or not sustained over time, or a combination thereof. In some embodiments, the optimized solid substrates for promoting cell or tissue growth or restored function and uses of same, address a need in populations with therapeutic results significantly greater than the surgical standard of care. In some embodiments, the optimized solid substrates for promoting cell or tissue growth or restored function and uses of same, address treating or repairing a large osteochondral, bone or cartilage lesion site in a subject in need thereof.

The invention comprises various materials and methods for the formation of bone within a patient using implanted bodies that are seeded with bone forming cells. The implants of the invention may comprise interlocking building blocks which allow for the formation of any desired structure. The geometry of the resulting bone structure can be tailored with great precision, and can be controllably integrated with native bone as desired. Advantageously, the methods result in the formation of functional, structured bone and avoid overgrowth, undergrowth, and the use of growth factors such as BMP-2.

A method for manufacturing a sterile bio-ink includes providing an extracellular matrix composition, and the extracellular matrix composition being in a liquid state; adding an animal-based gel and a plant-based gel that are freeze-dried, re-dissolved, and filtered to the extracellular matrix composition, and mixing the extracellular matrix composition, the animal-based gel, and the plant-based gel to obtain a gel mixture; and centrifuging and degassing the gel mixture to obtain the bio-ink.

In alternative embodiments, provided are compositions, including products of manufacture, pharmaceutical compositions and kits, and methods, for treating, ameliorating, preventing or reducing the growth of, a biofilm, such as a biofilm in an oral environment, such as a biofilm growing on or adherent to a tooth an implant, or an oral prosthetic, or microbial colonies found in biofilms. In alternative embodiments, provided are compositions, including products of manufacture and kits, and methods, for treating, ameliorating, preventing or reducing the severity of an infection. In alternative embodiments, antibacterial and therapeutic formulations as provided and used herein are derived or isolated from Streptococcus sanguinis and/or Staphylococcus epidermidis organisms or cultures.